Compare United States Copper Index Fund (CPER) vs GeneDx Holdings Corp (WGS) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
United States Copper Index Fund vs GeneDx Holdings Corp — how do they compare? United States Copper Index Fund trades at $40.31 (market cap $708.28M), while GeneDx Holdings Corp trades at $67.33 (market cap $2.02B). The key difference: GeneDx Holdings Corp is far larger — about 2.9× United States Copper Index Fund's market cap, and United States Copper Index Fund is trading nearer its 52-week high, GeneDx Holdings Corp nearer its low. Which is the better fit depends on your goals — on Pluang, investors hold United States Copper Index Fund for 49 Days and GeneDx Holdings Corp for 19 Days on average.
| CPER | WGS | |
|---|---|---|
Market Cap | $708.28M | $2.02B |
Volume | 339,046 | 734,640 |
Sector | Commodities - Metals/Agriculture | Health |
52-Week High | $41.43 | $167.51 |
52-Week Low | $30.27 | $34.51 |
Typical Hold Time | 49 Days | 19 Days |
Enterprise Value | — | $2.05B |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
CPER is trading at $39.46, down 0.88% with bearish technical signals from moving averages. The stock faces headwinds amid copper market volatility despite positive long-term demand outlook for AI infrastructure. Recent news highlights copper's critical role in technology while mining operations face supply challenges.
The stock presents a cautious outlook with technical weakness offset by copper's strategic importance. Investment opportunity exists in copper's AI-driven demand growth, but risks include mining disruptions and price volatility. Current sentiment leans bearish with institutional caution on near-term performance.
GeneDx (WGS) trades at $67.73, down 1.17% with bearish technical signals despite recent earnings beats. The company shows strong revenue growth to $454M in 2026 but faces profitability challenges with a -23.4% net margin. Recent developments include new genomic testing products and hospital partnerships, while analyst consensus remains strongly bullish with a $81 price target.
The stock presents a growth story with expanding genomic testing volumes but carries significant execution risk given negative profitability metrics. Upside potential exists if management can translate revenue growth into sustainable profits, though current cash flow trends and high valuation multiples warrant caution for risk-averse investors.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
About United States Copper Index Fund
CPER is a commodity ETF that tracks the price of copper futures via the SummerHaven Copper Index. It provides direct exposure to the 'red metal' using a rules-based strategy to select futures contracts, making it a key tool for hedging or betting on industrial growth and electrification.
Read more on CPER →About GeneDx Holdings Corp
GeneDx is a patient-centered health intelligence company that specializes in transforming healthcare through the application of genomics. It combines advanced technology with one of the world's largest rare disease genomic datasets to provide clinical-grade exome and genome sequencing, enabling precise and rapid diagnosis for patients with complex medical conditions.
Read more on WGS →
